Weight management meds, anaesthesia warning

The TGA has required updates to medicines information documents for GLP-1 and dual GIP/GLP-1 receptor agonists, due to risk during deep sedation or anaesthesia The Therapeutic Goods Administration has issued a statement pointing out that all medicines in these “relatively new and high-profile classes” carry this risk. The list includes Ozempic (semaglutide), Trulicity (dulaglutide) and